Obstructive benign prostatic hyperplasia: Therapeutical aspects

被引:6
作者
Altwein, JE [1 ]
机构
[1] Krankenhaus Barmherzigen Bruder, Dept Urol, D-80639 Munich, Germany
关键词
prostatic hyperplasia; therapeutic modalities; treatment selection;
D O I
10.1159/000052273
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: Once benign prostatic obstruction (BPO) is diagnosed, the urologist is confronted with an array of therapeutic modalities, from which he has to choose. The decision can be based on the patient's desire, deobstructing efficacy, durability, cost and on the physician's experience as well as availability of modalities. Methods: A therapeutic spectrum is constructed for individualization of therapeutic options in evaluation of the relevant factors based on the published studies. Results: In treating BPO the surgical treatment (TURP, TUIP) is still the most reliable in experienced hands, and its cost-efficacy has to be weighed against durability. If LUTS without intravesical obstruction dominates, a-blocker or finasteride (prostates >40 g) are useful and more efficient than watchful waiting when symptom relief and uroflow improvement are outcome parameters. Interventional treatment modalities remain a moving target, since even high-energy TUMT does not overcome obstruction. Ablation techniques (Holmium laser, TEVAP) have not been used with regard to durability. Conclusion: Picking an inappropriate modality or selecting the wrong patient may lead to a cascade of therapies. One can obtain a change in paradigms to measure the outcome putting emphasis on cost, need to retreat and, last but not least, quality of life.
引用
收藏
页码:31 / 37
页数:7
相关论文
共 24 条
[1]   A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha(1A)-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia) [J].
Abrams, P ;
Speakman, M ;
Stott, M ;
Arkell, D ;
Pocock, R .
BRITISH JOURNAL OF UROLOGY, 1997, 80 (04) :587-596
[2]   Transurethral microwave thermotherapy (Prostatron(TM) version 2.5) compared with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: A randomized, controlled, parallel study [J].
Ahmed, M ;
Bell, T ;
Lawrence, WT ;
Ward, JP ;
Watson, GM .
BRITISH JOURNAL OF UROLOGY, 1997, 79 (02) :181-185
[3]   Transurethral microwave thermotherapy - Pilot study on the value of the Dornier urowave [J].
Almer, FM ;
Fretschner, M ;
Harzmann, R ;
Altwein, JE .
AKTUELLE UROLOGIE, 1996, 27 (05) :275-280
[4]   Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia [J].
Andersen, JT ;
Nickel, JC ;
Marshall, VR ;
Schulman, CC ;
Boyle, P .
UROLOGY, 1997, 49 (06) :839-845
[5]   An economic evaluation of finasteride for treatment of benign prostatic hyperplasia [J].
Baladi, JF ;
Menon, D ;
Otten, N .
PHARMACOECONOMICS, 1996, 9 (05) :443-454
[6]   Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials [J].
Boyle, P ;
Gould, AL ;
Roehrborn, CG .
UROLOGY, 1996, 48 (03) :398-405
[7]  
Chen ZX, 1997, J UROLOGY, V157, P2166, DOI 10.1016/S0022-5347(01)64704-9
[8]   Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia [J].
Chirikos, TN ;
Sanford, E .
JOURNAL OF UROLOGY, 1996, 155 (04) :1311-1316
[9]  
DaSilva FC, 1997, EUR UROL, V31, P272
[10]   DIFFERENCES IN OUTCOME OF TRANSURETHRAL RESECTION OF THE PROSTATE FOR BENIGN PROSTATIC HYPERTROPHY BETWEEN 3 DIAGNOSTIC CATEGORIES [J].
DOLL, HA ;
BLACK, NA ;
MCPHERSON, K ;
WILLIAMS, GB ;
SMITH, JC .
BRITISH JOURNAL OF UROLOGY, 1993, 72 (03) :322-330